ArticlePloS one2012
Statistical properties and robustness of biological controller-target networks.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Role of MicroRNAs in Renal Parenchymal Diseases-A New Dimension.International journal of molecular sciences · 2018Review
- Gene expression profiles and signaling mechanisms in αBMC systems biology · 2017Article
- Arsenic trioxide increases expression of secreted frizzled-related protein 1 gene and inhibits the WNT/β-catenin signaling pathway in Jurkat cells.Experimental and therapeutic medicine · 2017Article
- Classical and Novel TSPO Ligands for the Mitochondrial TSPO Can Modulate Nuclear Gene Expression: Implications for Mitochondrial Retrograde Signaling.International journal of molecular sciences · 2017Article
- A scalable method for molecular network reconstruction identifies properties of targets and mutations in acute myeloid leukemia.Journal of computational biology : a journal of computational molecular cell biology · 2015Article
- Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression.BMC systems biology · 2014Article
- Article
- Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.PloS one · 2014Article
- Systems biology of complex symptom profiles: capturing interactivity across behavior, brain and immune regulation.Brain, behavior, and immunity · 2013Review
- A quantitative model of normal Caenorhabditis elegans embryogenesis and its disruption after stress.Developmental biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cells are regulated by networks of controllers having many targets, and targets affected by many controllers, in a "many-to-many" control structure. Here we study several of these bipartite (two-layer) networks. We analyze both naturally occurring biological networks (composed of transcription factors controlling genes, microRNAs controlling mRNA transcripts, and protein kinases controlling protein substrates) and a drug-target network composed of kinase inhibitors and of their kinase targets. Certain statistical properties of these biological bipartite structures seem universal across systems and species, suggesting the existence of common control strategies in biology. The number of controllers is ∼8% of targets and the density of links is 2.5%±1.2%. Links per node are predominantly exponentially distributed. We explain the conservation of the mean number of incoming links per target using a mathematical model of control networks, which also indicates that the "many-to-many" structure of biological control has properties of efficient robustness. The drug-target network has many statistical properties similar to the biological networks and we show that drug-target networks with biomimetic features can be obtained. These findings suggest a completely new approach to pharmacological control of biological systems. Molecular tools, such as kinase inhibitors, are now available to test if therapeutic combinations may benefit from being designed with biomimetic properties, such as "many-to-many" targeting, very wide coverage of the target set, and redundancy of incoming links per target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.